Morbidity and Mortality of Radical Nephrectomy for Patients With Disseminated Cancer: An Analysis of the National Surgical Quality Improvement Program Database.
To determine the effect of disseminated cancer on perioperative outcomes following radical nephrectomy.



We conducted a retrospective cohort study of patients undergoing radical nephrectomy for kidney cancer from 2005 to 2014 using the American College of Surgeons National Surgical Quality Improvement Program, a multi-institutional prospective registry that captures perioperative surgical complications. Patients were stratified according to the presence (n = 657) or absence (n = 7143) of disseminated cancer at the time of surgery. We examined major complications (death, reoperation, cardiac event, or neurologic event) within 30 days of surgery. Secondary outcomes included pulmonary, infectious, venous thromboembolic, and bleeding complications; prolonged length of stay; and concomitant procedures (bowel, liver, spleen, pancreas, and vascular procedures). Adjusted odds ratio (aOR) and 95% confidence interval (95% CI) were calculated using multivariate logical regression models.



Patients with disseminated cancer were older and more likely to be male, have greater comorbidities, and have undergone open surgery. Major complications were more common among patients with disseminated cancer (7.8%) than those without disseminated cancer (3.2%; aOR 2.01, 95% CI 1.46-2.86). Mortality was significantly higher in patients with disseminated cancer (3.2%) than those without disseminated cancer (0.5%; P < .0001). Pulmonary (aOR 1.68, 95% CI 1.09-2.59), thromboembolic (aOR 1.72, 95% CI 1.01-2.96), and bleeding complications (aOR 2.12, 95% CI 1.73-2.60) were more common among patients with disseminated cancer as was prolonged length of stay (aOR 1.27, 95% CI 1.06-1.53).



Nephrectomy in patients with disseminated cancer is a morbid operation with significant perioperative mortality. These data may be used for preoperative counseling of patients undergoing cytoreductive nephrectomy.
Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
Christopher J D
CJ
Wallis
Division of Medical Oncology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
Georg
G
Bjarnason
Division of General Surgery, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
James
J
Byrne
Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
Douglas C
DC
Cheung
Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
Azik
A
Hoffman
Division of Urology, Department of Surgery, Princess Margaret Hospital and University Health Network, University of Toronto, ON, Canada.
Girish S
GS
Kulkarni
Division of General Surgery, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
Avery B
AB
Nathens
Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
Robert K
RK
Nam
Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada. Electronic address: raj.satkunasivam@gmail.com.
Raj
R
Satkunasivam
D000368:Aged; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D009392:Nephrectomy / Q000009:adverse effects* / Q000379:methods / Q000401:mortality*; D011183:Postoperative Complications / Q000453:epidemiology* / Q000209:etiology*; D058996:Quality Improvement; D012189:Retrospective Studies; D014481:United States